Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen [CNBC]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: CNBC
The pen could serve as a more convenient option for some patients, as it reduces the number of devices they have to use in a month to take the drug. Prices start at $299 for the lowest dose level on Eli Lilly's direct-to-consumer site, LillyDirect. In this article An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024. Shelby Knowles | Bloomberg | Getty Images Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. The pen could serve as a more convenient option for some patients, as it reduces the number of devices they have to use in a month to take the drug. Patients can use one pen to take four weekly doses of Zepbound. Currently, patients on the treatmen
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (LLY) is now covered by Royal Bank Of Canada. They set an "outperform" rating on the stock.MarketBeat
- Novo downgraded at J.P. Morgan as next-gen obesity drug trails Lilly's Zepbound [Seeking Alpha]Seeking Alpha
- Analysis-Novo's stumbles burnish Lilly's widening lead in weight-loss drugs [Yahoo! Finance Canada]Yahoo! Finance Canada
- Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen [MSNBC.com]MSNBC.com
- Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPenPR Newswire
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 2/19/26 - Form 4
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- LLY's page on the SEC website